Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors

被引：51

作者：

Michaelides, MR ^{[1
]}

Dellaria, JF ^{[1
]}

Gong, J ^{[1
]}

Holms, JH ^{[1
]}

Bouska, JJ ^{[1
]}

Stacey, J ^{[1
]}

Wada, CK ^{[1
]}

Heyman, HR ^{[1
]}

Curtin, ML ^{[1
]}

Guo, Y ^{[1
]}

Goodfellow, CL ^{[1
]}

Elmore, IB ^{[1
]}

Albert, DH ^{[1
]}

Magoc, TJ ^{[1
]}

Marcotte, PA ^{[1
]}

Morgan, DW ^{[1
]}

Davidsen, SK ^{[1
]}

机构：

[1] Abbott Labs, Canc Res Area, Dept 47J, Abbott Pk, IL 60064 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2001年 / 11卷 / 12期

关键词：

D O I：

10.1016/S0960-894X(01)00031-2

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A novel series of biaryl ether reverse hydroxamate MMP inhibitors has been developed. These compounds are potent MMP-2 inhibitors with limited activity against MMP-1. Select members of this series exhibit excellent pharmacokinetic properties with long elimination half-lives (7 h) and high oral bioavailability (100%). (C) 2001 Elsevier Science Ltd. All rights reserved.

引用

页码：1553 / 1556

页数：4

共 9 条

[1]

[Anonymous], ANN REP MED CHEM

[2] Broad spectrum matrix metalloproteinase inhibitors:: An examination of succinamide hydroxamate inhibitors with P1Cα gem-disubstitution [J].

Curtin, ML ;

Garland, RB ;

Davidsen, SK ;

Marcotte, PA ;

Albert, DH ;

Magoc, TJ ;

Hutchins, C .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (12) :1443-1448

[3] Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770 [J].

Curtin, ML ;

Florjancic, AS ;

Heyman, HR ;

Michaelides, MR ;

Garland, RB ;

Holms, JH ;

Steinman, DH ;

Dellaria, JF ;

Gong, J ;

Wada, CK ;

Guo, Y ;

Elmore, IB ;

Tapang, P ;

Albert, DH ;

Magoc, TJ ;

Marcotte, PA ;

Bouska, JJ ;

Goodfellow, CL ;

Bauch, JL ;

Marsch, KC ;

Morgan, DW ;

Davidsen, SK .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (12) :1557-1560

[4] Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR [J].

Hajduk, PJ ;

Sheppard, G ;

Nettesheim, DG ;

Olejniczak, ET ;

Shuker, SB ;

Meadows, RP ;

Steinman, DH ;

Carrera, GM ;

Marcotte, PA ;

Severin, J ;

Walter, K ;

Smith, H ;

Gubbins, E ;

Simmer, R ;

Holzman, TF ;

Morgan, DW ;

Davidsen, SK ;

Summers, JB ;

Fesik, SW .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1997, 119 (25) :5818-5827

[5]

Michaelides MR, 1999, CURR PHARM DESIGN, V5, P787

[6] N-formyl hydroxylamine containing dipeptides:: Generation of a new class of vasopeptidase inhibitors [J].

Robl, JA ;

Simpkins, LM ;

Asaad, MM .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (03) :257-260

[7] Matrix metalloproteinase inhibitors for treatment of cancer [J].

Skiles, JW ;

Monovich, LG ;

Jeng, AY .

ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 35, 2000, 35 :167-176

[8]

White AD, 1997, CURR PHARM DESIGN, V3, P45

[9] Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer [J].

Wojtowicz-Praga, S ;

Torri, J ;

Johnson, M ;

Steen, V ;

Marshall, J ;

Ness, E ;

Dickson, R ;

Sale, M ;

Rasmussen, HS ;

Chiodo, TA ;

Hawkins, MJ .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) :2150-2156

← 1 →